FiercePharmaPolitics—With 'LIBERATE' tweets, Trump seems to endorse lockdown protests

Closed sign in the window of a bar
As political leaders debate over reopening timing, Trump has appeared to back protests against lockdowns. (josephmok / iStock / Getty Images Plus)

Welcome to the FiercePharma political roundup, where each Monday we’ll highlight political developments that could affect the pharmaceutical industry. 

As the U.S. economic toll from COVID-19 lockdowns continues to mount—with tens of millions out of work and businesses suffering—the discussion has turned to reopening the economy even as confirmed cases nationwide continue to climb.  

Those emotions played out last week and over the weekend in places like Lansing, Michigan, and Austin, Texas, where protesters gathered to voice disapproval of lockdowns aimed at slowing the spread of the virus.

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Trump seemed to get behind the protests by tweeting “LIBERATE MICHIGAN,” “LIBERATE MINNESOTA,” and more on Friday. Those tweets followed a protest in Lansing, where people congregated at Michigan’s capitol building.

They preceded a protest in Austin, Texas, where hundreds gathered. New York Times Houston bureau chief Manny Fernandez was on the scene and documented the gathering.

Thousands gathered Sunday in Denver as well, the New York Post reports.

At his task force briefing on Sunday, Trump said some governors have “gone too far” with stay-at-home orders. In Michigan, certain stay-at-home measures weren’t “necessary or appropriate,” he said. 

“Some of the things that happened are maybe not so appropriate," he said, as quoted by The Hill. "And I think in the end it’s not going to matter because we're starting to open up our states, and I think they're going to open up very well." 

RELATED: Coronavirus tracker: Novartis trial tackles the chloroquine question; NIH, Gilead post new remdesivir animal results

Trump initially declared that he'd be the one to decide when and how to open back up, but then said governors would "call your own shots” around reopening. 

The timing of reopening is weighing on Americans’ minds as COVID-19 deaths and cases mount. Early Monday, the U.S. passed the 40,000 death threshold, and more than three-quarters of a million infections have been detected, according to the Johns Hopkins University. 

RELATED: 'Firing Fauci' and #SaveFauci trend after Trump retweet 

Amid that backdrop, 60% of Americans favor longer stay-at-home orders over reopening society to jumpstart the economy, according to a poll released Sunday by NBC News and the Wall Street Journal. 

Last week, the Trump administration rolled out guidelines for reopening that would allow areas to reopen in phases over time. The guidelines set out which businesses should open during which phases, and the timing for an area to proceed through the process. 

SPECIAL REPORT: The top 15 biopharma M&A mistakes of the last decade

Some experts worry about the lack of adequate testing for reopening. Harvard researchers recently concluded the U.S. needs to conduct three times as many tests as it's currently doing to reopen, the New York Times reports.

Read more on

Suggested Articles

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.

BioCryst has scored FDA approval for Orladeyo, the first oral option to prevent hereditary angioedema attacks in patients 12 and older.